课题基金 / 基金详情

GLIPIZIDE-GITS AND METFORMIN ALONE VS COMBINATION THERAPY IN NIDDM

GLIPIZIDE-GITS AND METFORMIN ALONE VS COMBINATION THERAPY IN NIDDM
格列吡嗪和二甲双胍单独治疗与联合治疗 NIDDM
批准号:
6123137
负责人:
MICHAEL BERELOWITZ
金额:
$5.08万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

MICHAEL BERELOWITZ的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
SPECIFIC AIMS 1. To compare the effect of oral hypoglycemic agents Glipizide-GITS and Metformin alone or in combination on hepatic glucose production in patients with NIDDM. 2. To compare insulin secretory responses to Sustacal in patients with NIDDM receiving Glipizide-GITS or Metformin alone or in combination. It is the hypothesis of this proposal that the combination of an oral hypoglycemic agent that improves insulin secretion (Glipizide) with one that improves insulin action (Metformin) in the treatment regiment of NIDDM patients will provide improved glycemia compared to either agent alone through a synergistic effect on insulin secretion and action.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GLIPIZIDE-GITS AND METFORMIN ALONE VS COMBINATION THERAPY IN NIDDM
SOMATOSTATIN PHYSIOLOGY IN DIABETES AND OBESITY
海外基金